// App-Quantinova.ai

e16556 : Biomarker Exploration for neoadjuvant chemotherapy with gemcitabine combined with cisplatin in muscle-invasive bladder cancer.

Researchers

Presenter

  • Kun Wang

Principal Investigators

  • Xusheng Chen

  • Zhenting Zhang

  • Hailong Hu

  • Aili Zhang

  • Xin Wang

  • Lijun Chen

  • Zhizhong Liu

  • Changjiu Yue

  • Xueying Zhang

  • Menghuan Zhang

  • Xin Yao

Medical Centers

  • Tianjin Medical University Cancer Hospital, Tianjin, China

  • Tianjin Medical University Cancer Hospital, Tianjin, China

  • Breast canter, Fourth Hospital of Hebei Medical University, Shijiazhuang, China

  • Breast canter, Fourth Hospital of Hebei Medical University, Shijiazhuang, China

  • The Fifth Medical Center of the Chinese Peoples Liberation Army (PLA) General Hospital, Beijing, China

  • Hospitals in Inner Mongolia autonomous region, Baotou, China

  • GloriousMed Clinical Laboratory Co., Ltd., Shanghai, China

  • Research Institute, GloriousMed Clinical Laboratory Co., Ltd., Shanghai, China

  • Tianjin Medical University Cancer Hospital, Tianjin, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved